繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
牛牛AI助理已提取核心訊息
Applied DNA Sciences reported a significant revenue decline for fiscal year 2024, with total revenue dropping 75% to $3.43 million from $13.37 million in FY2023. The decrease was primarily due to reduced COVID-19 testing demand. Net loss narrowed to $7.09 million from $10.02 million year-over-year.The company is shifting its focus to Therapeutic DNA Production Services, aiming to capitalize on the growing mRNA therapeutics market. It plans to complete a GMP manufacturing facility for DNA templates by January 2025. Applied DNA also launched its Linea IVT platform for mRNA production in July 2023 following an acquisition.To strengthen its financial position, Applied DNA raised $6.5 million in a public offering in October 2024. However, the company received a Nasdaq delisting notice in November for failing to meet the $1 minimum bid price requirement. Management intends to implement a reverse stock split to regain compliance, unless the stock price recovers within 30 days of shareholder approval.
Applied DNA Sciences reported a significant revenue decline for fiscal year 2024, with total revenue dropping 75% to $3.43 million from $13.37 million in FY2023. The decrease was primarily due to reduced COVID-19 testing demand. Net loss narrowed to $7.09 million from $10.02 million year-over-year.The company is shifting its focus to Therapeutic DNA Production Services, aiming to capitalize on the growing mRNA therapeutics market. It plans to complete a GMP manufacturing facility for DNA templates by January 2025. Applied DNA also launched its Linea IVT platform for mRNA production in July 2023 following an acquisition.To strengthen its financial position, Applied DNA raised $6.5 million in a public offering in October 2024. However, the company received a Nasdaq delisting notice in November for failing to meet the $1 minimum bid price requirement. Management intends to implement a reverse stock split to regain compliance, unless the stock price recovers within 30 days of shareholder approval.
Applied DNA Sciences在2024財年的營業收入出現顯著下降，總收入從2023財年的1337萬降至343萬，下降幅度爲75%。這一下降主要是由於COVID-19檢測需求減少。淨虧損從去年的1002萬縮小至709萬。該公司正轉向治療性DNA生產服務，旨在利用日益增長的mRNA治療市場。計劃在2025年1月之前完成DNA模板的GMP製造設施。Applied DNA還於2023年7月在收購後推出了其mRNA生產的Linea IVt平台。爲了增強財務狀況，Applied DNA在2024年10月通過公開募股募集了650萬。然而，該公司在11月收到納斯達克退市通知，原因是未能滿足1美元的最低買盤價格要求。管理層打算實施反向股票拆分以重新獲得合規資格，除非股票價格在股東批准後的30天內恢復。
Applied DNA Sciences在2024財年的營業收入出現顯著下降，總收入從2023財年的1337萬降至343萬，下降幅度爲75%。這一下降主要是由於COVID-19檢測需求減少。淨虧損從去年的1002萬縮小至709萬。該公司正轉向治療性DNA生產服務，旨在利用日益增長的mRNA治療市場。計劃在2025年1月之前完成DNA模板的GMP製造設施。Applied DNA還於2023年7月在收購後推出了其mRNA生產的Linea IVt平台。爲了增強財務狀況，Applied DNA在2024年10月通過公開募股募集了650萬。然而，該公司在11月收到納斯達克退市通知，原因是未能滿足1美元的最低買盤價格要求。管理層打算實施反向股票拆分以重新獲得合規資格，除非股票價格在股東批准後的30天內恢復。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間